1
|
Marcy PY, Dahlet C, Brenet O, Yazbec G, Dubois PY, Salm B, Fouche Y, Mari V, Montastruc M, Lebrec N, Ancel B, Paillocher N, Dupoiron D, Rangeard O, Michel C, Chateau Y, Ettaiche M, Ferrero JM, Chamorey E. [Multicenter validation study of a questionnaire assessing patient satisfaction with and acceptance of totally-implanted central venous access devices]. Bull Cancer 2015; 102:301-15. [PMID: 25799876 DOI: 10.1016/j.bulcan.2015.02.012] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2014] [Accepted: 01/29/2015] [Indexed: 11/26/2022]
Abstract
OBJECTIVE Most cancer patients require a totally-implanted central venous access device (TIVAD) for their treatment. This was a prospective, multicenter, open study to: (i) develop and validate a French-language questionnaire dubbed QASICC (Questionnaire for Acceptance of and Satisfaction with Implanted Central Venous Catheter) assessing patient's satisfaction with and acceptance of their TIVAD; (ii) develop a mean score of patient's acceptance and satisfaction; (iii) look for correlation between QASICC score and TIVAD patient/tumor pathology/device characteristics. METHODS From 2011 November to 2012 December, the first version of the QASICC questionnaire that included 27 questions assessing seven dimensions was re-tested among 998 cancer patients in eleven French cancer hospitals (eight cancer research institutes and three university/general hospitals). The goal was: (i) to reduce the questionnaire item and dimension number (pertinency, saturation effect, item correlation); (ii) to assess its psychometric properties, demonstrate its validity and independency compared to (EORTC) QLQC30; (iii) to correlate clinical and pathological patient's/tumor's/TIVAD's parameters with the QASICC questionnaire score (the higher the overall score, the greater the acceptance and satisfaction). The questionnaire was administered to the patient 30 days (±15 days) after TIVAD's implantation. RESULTS Among 998 questionnaires given to cancer patients, 658 were analyzed and 464 were fully assessed as there was no missing data. Time to fill-in the questionnaire was five minutes in 90% patients. Final QASICC tool included twenty-two questions assessing four homogeneous dimensions (65%<Cronbach coefficient<85%): (i) impact on daily activities and professional activities; (ii) esthetics and privacy; (iii) pain, contribution to the comfort of the treatment; (iv) local discomfort. Respective assessment scores were 23.6%, 32.9%, 20.4% and 18.0%. Overall satisfaction score was 75.8%; global assessment score was 76.2%. These scores were significantly linked to patient's gender, anesthesia type, TIVAD's implantation side, patient's age and tumor type. CONCLUSIONS This second and final methodological and statistical validation of this auto-questionnaire QASICC allows us to propose it as a dedicated questionnaire to TIVAD's cancer patients by using a score assessing acceptance and satisfaction regarding their device.
Collapse
Affiliation(s)
- Pierre Yves Marcy
- Centre Antoine-Lacassagne, 33, avenue de Valombrose, 06189 Nice cedex 1, France.
| | - Christian Dahlet
- Centre Paul-Strauss, 03, rue de la Porte de l'Hôpital, 67065 Strasbourg cedex, France
| | - Olivier Brenet
- Centre Paul-Papin, ICO, 2, rue Moll, 49933 Angers cedex 9, France
| | - Gabriel Yazbec
- Institut Jean-Godinot, 01, avenue du Général-Koenig, BP171, 51056 Reims cedex, France
| | - Pierre Yves Dubois
- Institut Jean-Godinot, 01, avenue du Général-Koenig, BP171, 51056 Reims cedex, France
| | - Bernard Salm
- Centre Alexis-Vautrin, 6, avenue de Bourgogne, 54511 Vandœuvre-lès-Nancy, France
| | - Yves Fouche
- Centre Antoine-Lacassagne, 33, avenue de Valombrose, 06189 Nice cedex 1, France
| | - Veronique Mari
- Hôpital de Jour, centre Antoine-Lacassagne, 33, avenue de Valombrose, 06189 Nice cedex 1, France
| | - Marion Montastruc
- Institut Claudius-Rigaud, 20-24, rue du Pont-Saint-Pierre, 31052 Toulouse cedex, France
| | - Nathalie Lebrec
- Centre Paul-Papin, ICO, 2, rue Moll, 49933 Angers cedex 9, France
| | - Benoit Ancel
- Centre Alexis-Vautrin, 6, avenue de Bourgogne, 54511 Vandœuvre-lès-Nancy, France
| | | | - Denis Dupoiron
- Centre Paul-Papin, ICO, 2, rue Moll, 49933 Angers cedex 9, France
| | - Olivier Rangeard
- Centre Alexis-Vautrin, 6, avenue de Bourgogne, 54511 Vandœuvre-lès-Nancy, France
| | - Cécile Michel
- Unité de recherche clinique, département de recherche clinique, innovation et statistiques, centre Antoine-Lacassagne, 33, avenue de Valombrose, 06189 Nice cedex 02, France
| | - Yann Chateau
- Unité d'épidémiologie et de biostatistiques, département de recherche clinique, innovation et statistiques, centre Antoine-Lacassagne, 33, avenue de Valombrose, 06189 Nice cedex 02, France
| | - Marc Ettaiche
- Unité d'épidémiologie et de biostatistiques, département de recherche clinique, innovation et statistiques, centre Antoine-Lacassagne, 33, avenue de Valombrose, 06189 Nice cedex 02, France
| | - Jean-Marc Ferrero
- Unité de recherche clinique, département de recherche clinique, innovation et statistiques, centre Antoine-Lacassagne, 33, avenue de Valombrose, 06189 Nice cedex 02, France
| | - Emmanuel Chamorey
- Unité d'épidémiologie et de biostatistiques, département de recherche clinique, innovation et statistiques, centre Antoine-Lacassagne, 33, avenue de Valombrose, 06189 Nice cedex 02, France
| |
Collapse
|